Verteporfin Photodynamic Therapy + Ranibizumab
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Polypoidal Choroidal Vasculopathy
Conditions
Polypoidal Choroidal Vasculopathy
Trial Timeline
Apr 1, 2008 → —
NCT ID
NCT00674323About Verteporfin Photodynamic Therapy + Ranibizumab
Verteporfin Photodynamic Therapy + Ranibizumab is a approved stage product being developed by Novartis for Polypoidal Choroidal Vasculopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT00674323. Target conditions include Polypoidal Choroidal Vasculopathy.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00674323 | Approved | Completed |
Competing Products
9 competing products in Polypoidal Choroidal Vasculopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Zimura + Eylea | Astellas Pharma | Phase 2 | 52 |
| Avacincaptad Pegol | Astellas Pharma | Phase 2 | 52 |
| Brolucizumab 6mg + Brolucizumab 6mg | Novartis | Phase 3 | 77 |
| Intravitreal aflibercept injection 2.0mg | Regeneron Pharmaceuticals | Approved | 84 |
| Rescue Intravitreal Aflibercept Injection | Regeneron Pharmaceuticals | Approved | 84 |
| Aflibercept Intravitreous Injection | Bayer | Approved | 82 |
| aflibercept 8 mg | Bayer | Phase 3 | 74 |
| aflibercept | Bayer | Approved | 82 |
| ranibizumab intravitreal injection | Pacific Biosciences | Phase 1 | 25 |